CD8A and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Importantly, the identification of these TCF1+ CD8+ T cells may guide treatment for patients with tRCC, which is a rare malignancy without a consensus first-line treatment option.